Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Depatuxizumab [USAN]
RN: 1471999-69-5
UNII: W984C353CG

Notes

  • NCI: A humanized monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) with antineoplastic activity. MoAb ABT-806 targets the EGFR deletion variant, de2-7 EGFR as well as wild-type EGFR expressed in cells overexpressing the receptor, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization result in an inhibition in signal transduction and anti-proliferative effects. This MoAb targets cells expressing aberrant EGFR, hence making it an ideal candidate for generation of radioisotope or toxin conjugates. (NCI Thesaurus)
  • Targets epidermal growth factor receptor; has antineoplastic activity; in phase 1 clinical trials (2015).

Molecular Formula

  • C6428-H9920-N1704-O2008-S42 (peptide)
 

Classification Code

  • Treatment of Cancer
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • ABT-806
  • Depatuxizumab [USAN]

Synonyms

  • ABT 806
  • ABT-806
  • Anti-egfr mab ABT-806
  • Anti-egfr moab ABT-806
  • Anti-egfr monoclonal antibody ABT-806
  • Depatuxizumab
  • Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mus musculus monoclonal ABT-806 heavy chain), disulfide with human-mus musculus monoclonal ABT-806 light chain, dimer
  • UNII-W984C353CG

Registry Numbers

CAS Registry Number

  • 1471999-69-5

FDA UNII

  • W984C353CG

System Generated Number

  • 1471999695